Nemes Rush Group LLC Bio Line Rx Ltd. Put Options Transaction History
Nemes Rush Group LLC
- $689 Billion
- Q3 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding BLRX
# of Institutions
40Shares Held
3.36MCall Options Held
46.5KPut Options Held
6.3K-
Alyeska Investment Group, L.P. Chicago, IL866KShares$2.91 Million0.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE816KShares$2.74 Million4.05% of portfolio
-
Envestnet Asset Management Inc239KShares$803,6640.0% of portfolio
-
Morgan Stanley New York, NY198KShares$663,7240.0% of portfolio
-
Values First Advisors, Inc.166KShares$559,2680.02% of portfolio
About BioLineRx Ltd.
- Ticker BLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,524,500
- Market Cap $207M
- Description
- BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...